Physician profile
Melvin C Murphy
NPI 1932288586
$7,975.60
in general payments reported to CMS, 2019-2025
40 companies · $735 in 2025
The $735 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,325 · 2020: $1,034 · 2021: $1,580 · 2022: $1,177 · 2023: $1,311 · 2024: $814 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,860.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,859.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,507.98 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,406.38 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $845.72 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $806.00 | 2021-2025 | |
| Glaxosmithkline, LLC. | $473.52 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $473.39 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $379.87 | 2019-2022 | |
| Astellas Pharma US INC | $345.91 | 2019-2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $217.41 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $190.91 | 2020-2022 | |
| Exact Sciences Corporation | $159.00 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.54 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $128.76 | 2019-2023 | Xarelto |
| Abbott Laboratories | $99.94 | 2021-2023 | Freestyle Libre 2 |
| Abbvie INC. | $66.91 | 2021-2023 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melvin Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.